L. Whitaker

发表

Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents

S. Puig, E. Gillanders, D. Elder, 2006, Journal of Medical Genetics.

Germline Variation at CDKN2A and Associations with Nevus Phenotypes among Members of Melanoma Families.

S. Puig, D. Bishop, D. Elder, 2017, The Journal of investigative dermatology.

prudent to ensure normal levels, and we feel that the wording of our article was appropriate.

J. Barrett, D. Bishop, D. Elder, 2010 .

Reply to P.E. Hutchinson et al

J. Barrett, D. Bishop, D. Elder, 2010 .

Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia

J. Malvehy, S. Puig, J. Barrett, 2014 .

Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom

J. Malvehy, S. Puig, J. Barrett, 2014, Hereditary cancer in clinical practice.

families from three continents mutations: a GenoMEL study of melanoma-prone Features associated with germline CDKN2A

S. Puig, E. Gillanders, D. Bishop, 2007 .

Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom

J. Malvehy, S. Puig, J. Barrett, 2014, Hereditary Cancer in Clinical Practice.

An assessment of a variant of the DNA repair gene XRCC3 as a possible nevus or melanoma susceptibility genotype.

J. Barrett, D. Bishop, I. Dos Santos Silva, 2004, The Journal of investigative dermatology.

Phenotypic and Histopathological Tumor Characteristics According to CDKN2A Mutation Status among Affected Members of Melanoma Families.

S. Puig, D. Bishop, D. Elder, 2016, The Journal of investigative dermatology.

Serum 25-hydroxyvitamin D3 levels are associated with breslow thickness at presentation and survival from melanoma.

J. Barrett, D. Bishop, D. Elder, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL.

S. Puig, E. Gillanders, D. Bishop, 2006, Cancer research.

A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family.

D. Bishop, M. Knowles, M. Harland, 2001, Human molecular genetics.

An assessment of the CDKN2A variant Ala148Thr as a nevus/melanoma susceptibility allele.

J. Barrett, D. Bishop, E. Pinney, 2002, The Journal of investigative dermatology.

Prevalence of 9p21 deletions in UK melanoma families

J. Barrett, D. Bishop, C. Taylor, 2005, Genes, chromosomes & cancer.

Melanoma risk for CDKN2A mutation carriers who are relatives of population-based case carriers in Australia and the UK

J. Barrett, D. Bishop, G. Giles, 2011, Journal of Medical Genetics.

The relationship between the epidermal growth factor (EGF) 5'UTR variant A61G and melanoma/nevus susceptibility.

J. Barrett, D. Bishop, A. Swerdlow, 2004, The Journal of investigative dermatology.

Overseas sun exposure, nevus counts, and premature skin aging in young English women: a population-based survey.

D. Bishop, T. Abramsky, I. D. S. Silva, 2009, The Journal of investigative dermatology.